ANDA 90870, held by PharmoBedient. Epinastine Hydrochloride.
As of Nov 21, 2026, ANDA 90870 (Epinastine Hydrochloride), held by PharmoBedient, was first approved by FDA on Mar 14, 2011, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 14, 2011 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Epinastine Hydrochloride0.05% · solution/drops;ophthalmic | Epinastine Hydrochloride | Discontinued |
| Jan 21, 2021 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 14, 2011 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters